Cell and Gene Therapy Catapult’s Annual Review 2021
- Published on 22nd November 2021 by Cell and Gene Therapy Catapult
The past year emphasised the strength and world-leading capabilities of the UK cell and gene therapy industry which experienced significant expansion despite the COVID-19 pandemic.
The Cell and Gene Therapy Catapult has published its 2021 Annual Review, highlighting that the UK has become a place of choice to set up advanced therapy medicinal products (ATMP) activities, with 29% of European ATMP companies operating in the country.
Click here to read the Cell and Gene Therapy Catapult’s Annual Review 2021.
Other news
-
Exploristics launches its KerusCloud Spring 2023 ReleasePublished on 25 May 2023 -
Ten tech-bio companies selected to take part in 2023 Catalyser ProgrammePublished on 23 May 2023 -
Kadans Announces Official Opening of Sycamore House, StevenagePublished on 18 May 2023
-
LifeArc announces strategic partnership with PrecisionLife as part of its Motor Neuron Disease Translational ChallengePublished on 15 May 2023
Copyright © 2023 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.